CN1479716A - 具有活化过氧化物酶体-增殖因子激活的受体α性质的丙酸衍生物 - Google Patents

具有活化过氧化物酶体-增殖因子激活的受体α性质的丙酸衍生物 Download PDF

Info

Publication number
CN1479716A
CN1479716A CNA018200885A CN01820088A CN1479716A CN 1479716 A CN1479716 A CN 1479716A CN A018200885 A CNA018200885 A CN A018200885A CN 01820088 A CN01820088 A CN 01820088A CN 1479716 A CN1479716 A CN 1479716A
Authority
CN
China
Prior art keywords
methyl
amino
phenyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018200885A
Other languages
English (en)
Chinese (zh)
Inventor
K���ڶ��Ͷ�˹
K·乌尔巴恩斯
M·沃尔特林
S·尼科利克
ж�
J·佩尔纳斯托尔菲
B·辛岑
���ϣ-�¸���˹
E·迪特里希-温根罗斯
H·比肖夫
-������ϣ����������
C·希尔斯-迪特里希
K·卢斯蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10124905A external-priority patent/DE10124905A1/de
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN1479716A publication Critical patent/CN1479716A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA018200885A 2000-10-05 2001-09-24 具有活化过氧化物酶体-增殖因子激活的受体α性质的丙酸衍生物 Pending CN1479716A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10049208.8 2000-10-05
DE10049208 2000-10-05
DE10124905.5 2001-05-22
DE10124905A DE10124905A1 (de) 2000-10-05 2001-05-22 Propionsäurederivate

Publications (1)

Publication Number Publication Date
CN1479716A true CN1479716A (zh) 2004-03-03

Family

ID=26007267

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018200885A Pending CN1479716A (zh) 2000-10-05 2001-09-24 具有活化过氧化物酶体-增殖因子激活的受体α性质的丙酸衍生物

Country Status (22)

Country Link
EP (1) EP1328508A2 (de)
JP (1) JP2004510757A (de)
CN (1) CN1479716A (de)
AU (1) AU2001293838A1 (de)
BG (1) BG107684A (de)
BR (1) BR0114437A (de)
CA (1) CA2424540A1 (de)
CZ (1) CZ2003964A3 (de)
EE (1) EE200300140A (de)
HN (1) HN2001000223A (de)
HR (1) HRP20030346A2 (de)
HU (1) HUP0302306A3 (de)
IL (1) IL155125A0 (de)
MA (1) MA25917A1 (de)
MX (1) MXPA03002901A (de)
NO (1) NO20031517L (de)
NZ (1) NZ525119A (de)
PL (1) PL361162A1 (de)
RU (1) RU2003112968A (de)
SK (1) SK4132003A3 (de)
UY (1) UY26951A1 (de)
WO (1) WO2002028821A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
CN107406484A (zh) * 2014-12-11 2017-11-28 中化帝斯曼制药有限公司荷兰公司 酰化环状肽的方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10151390A1 (de) * 2001-10-18 2003-05-08 Bayer Ag Essigsäurederivate
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
KR20050055773A (ko) * 2002-10-21 2005-06-13 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단
AU2003279996B2 (en) * 2002-10-21 2009-07-09 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes and their use
CA2503405A1 (en) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
AU2003296402A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Thiophene derivative ppar modulators
KR20110140139A (ko) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N-芳丙烯酰基取代的酪氨酸衍生物
KR100699928B1 (ko) * 2004-10-05 2007-03-26 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 알파 리간드를 제조하기위한 중간체의 제조방법
BRPI0519012A2 (pt) 2004-12-13 2008-12-23 Ono Pharmaceutical Co derivado do Ácido aminocarboxÍlico e seu uso medicinal
TW201022221A (en) 2008-12-01 2010-06-16 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivatives containing thiazole ring and pharmaceutical use thereof
JP5436941B2 (ja) * 2009-06-03 2014-03-05 あすか製薬株式会社 ラクタム化合物又はその塩及びppar活性化剤
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
CN107406484A (zh) * 2014-12-11 2017-11-28 中化帝斯曼制药有限公司荷兰公司 酰化环状肽的方法

Also Published As

Publication number Publication date
AU2001293838A1 (en) 2002-04-15
HN2001000223A (es) 2001-10-25
SK4132003A3 (en) 2004-02-03
RU2003112968A (ru) 2004-09-20
MXPA03002901A (es) 2003-10-15
CZ2003964A3 (cs) 2003-08-13
EP1328508A2 (de) 2003-07-23
BR0114437A (pt) 2003-07-01
HUP0302306A3 (en) 2005-02-28
IL155125A0 (en) 2003-10-31
EE200300140A (et) 2003-08-15
HRP20030346A2 (en) 2005-04-30
NO20031517D0 (no) 2003-04-03
BG107684A (bg) 2003-10-31
PL361162A1 (en) 2004-09-20
NZ525119A (en) 2005-04-29
JP2004510757A (ja) 2004-04-08
WO2002028821A2 (de) 2002-04-11
NO20031517L (no) 2003-05-28
UY26951A1 (es) 2002-06-20
HUP0302306A2 (hu) 2003-10-28
MA25917A1 (fr) 2003-10-01
WO2002028821A3 (de) 2002-08-15
CA2424540A1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
CN1213019C (zh) 磺酰胺和羧酰胺衍生物和含这种化合物作活性成分的药物
CN1479716A (zh) 具有活化过氧化物酶体-增殖因子激活的受体α性质的丙酸衍生物
CN1271066C (zh) 芳香二羧酸衍生物
CN1103332C (zh) 联苯基-5-链烷羧酸衍生物和其应用
CN1157368C (zh) 人过氧化物酶体增殖剂活化受体(PPAR)α激动剂-取代苯基丙酸衍生物
CN1289469C (zh) α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
CN1578659A (zh) 过氧化物酶体增殖剂激活的受体(ppar)的调节剂
CN1073428A (zh) 具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物,它们的制备及其在治疗上的应用
CN1251523A (zh) 磺酰胺衍生物
CN1942428A (zh) Cetp抑制剂
CN1468226A (zh) 联苯衍生物及其作为PPAR-γ型受体活化剂的用途
CN1551866A (zh) 羧酸衍生物化合物及包含这些化合物为活性成分的药物
US6548538B2 (en) Propionic acid derivatives
CN1503774A (zh) 羧酸衍生物及其盐
CN1437581A (zh) 胰高血糖素拮抗剂/反向激动剂
CN1842515A (zh) 组织蛋白酶抑制剂
CN1617854A (zh) 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用
CN1662230A (zh) 作为PPARα和γ调节剂的苯甲酸衍生物
CN1239472C (zh) Hiv整合酶抑制剂
CN1898219A (zh) 作为组织蛋白酶抑制剂的新的酮基噁二唑衍生物
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1662487A (zh) 酰胺连接基过氧化物酶体增殖物激活受体调节剂
CN1787989A (zh) 亚氨醚衍生化合物和含有该化合物作为活性成分的药物
CN1319938C (zh) 治疗胰岛素抵抗的邻位取代的苯甲酸衍生物
HK1063460A (en) Propionic acid derivatives with pparalpha activating properties

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1063460

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1063460

Country of ref document: HK